Here is what launched, what is launching, and what it means.
The Advancing Chronic Care with Effective, Scalable Solutions Model is a ten-year voluntary program beginning July 5, 2026. Applications opened in January. The first cohort deadline is April 1. Rolling admissions continue through 2033. Technical FAQs are available on the ACCESS FAQ page.
ACCESS addresses a structural problem in Original Medicare that has persisted for decades. Fee-for-service pays for defined activities. Technology-supported care, the kind delivered through telehealth platforms, wearable devices, remote monitoring, and coaching apps, does not map cleanly onto those defined activities. Providers who want to manage a patient's hypertension through a connected blood pressure cuff and an app-based coaching program have had no straightforward Medicare payment pathway. ACCESS creates one.
The model introduces Outcome-Aligned Payments. Participating organizations, which must be Medicare Part B enrolled providers or suppliers, receive recurring payments for managing patients' qualifying chronic conditions. Half arrives as quarterly installments. The other half is contingent on patients actually hitting clinical targets at reconciliation. A hypertension patient whose blood pressure drops 10 mmHg counts. A diabetes patient whose HbA1c improves counts. The payment rewards the outcome, and the provider chooses the method.
Four clinical tracks are live at launch. Early Cardio-Kidney-Metabolic covers hypertension, dyslipidemia, obesity with central adiposity, and prediabetes. Cardio-Kidney-Metabolic covers diabetes, chronic kidney disease stages 3a and 3b, and atherosclerotic cardiovascular disease. Musculoskeletal covers chronic pain. Behavioral Health covers depression and anxiety. CMS has signaled additional tracks may follow.
The first-year Outcome Attainment Threshold is 50 percent. An organization earns full payment if half its enrolled patients meet their targets. The threshold rises annually. Patients enroll voluntarily, either directly or through physician referral. They retain all standard Medicare benefits. Cost-sharing on the outcome-aligned payments can be waived.
CMS will publish a public directory listing each participant's tracks, tools, and risk-adjusted outcomes. Transparency is built into the design. Digital health companies that want to participate must enroll in Medicare Part B or partner with an entity that already has. CMS will also maintain a vendor tools directory to help participants find compliant software and hardware.
ACCESS matters because it is the first CMS model to build a dedicated payment lane for the kind of care that commercial payers and Medicare Advantage plans have been purchasing for years through per-member-per-month arrangements. Original Medicare's 30 million chronically ill fee-for-service beneficiaries have been locked out of that lane. ACCESS opens it.
TEAM
The Transforming Episode Accountability Model launched January 1, 2026. It is already running. It is mandatory.
TEAM is a five-year episode-based bundled payment program covering five high-volume, high-cost surgical procedures: lower extremity joint replacement, surgical hip and femur fracture treatment, spinal fusion, coronary artery bypass graft, and major bowel procedures. Together, these five categories accounted for nearly 900,000 inpatient and outpatient surgeries and roughly $18 billion in Medicare hospital payments in 2022.
The model applies to 741 acute care hospitals in 188 metropolitan areas, representing approximately 25 percent of Medicare beneficiaries. Selection was geographic, based on Core-Based Statistical Areas published in the FY 2025 IPPS final rule. If your hospital is in a selected CBSA, you participate. There is no opt-out.
The mechanism works like this. Each surgical episode begins when the patient is admitted or undergoes an outpatient procedure and ends 30 days after discharge. CMS sets a target price for each episode based on regional spending data, risk adjustments, and a three percent discount factor representing Medicare's share of the savings. If actual spending comes in below the target, the hospital earns a reconciliation payment. If spending exceeds the target, the hospital owes CMS.
Year one is a glide path. All hospitals default to Track 1 in 2026, which carries upside only, capped at 10 percent. Safety-net hospitals can remain in Track 1 through 2028. Urban non-safety-net hospitals move to Track 3, with symmetric risk up to 20 percent, in 2027. Rural hospitals can stay in Track 2, with 5 percent caps, for the full five years.
Quality measures include the CMS Patient Safety and Adverse Events Composite and, for joint replacements, a patient-reported outcome measure. Quality performance adjusts the reconciliation payment up or down.
TEAM is CMS's clearest statement that mandatory bundled payments are the future of surgical Medicare spending. Hospitals that have never participated in a value-based arrangement are now in one.
MAHA ELEVATE
Make America Healthy Again: Enhancing Lifestyle and Evaluating Value-based Approaches Through Evidence launches September 1, 2026. CMS will release the Notice of Funding Opportunity in early 2026 for the first cohort. A second cohort follows in 2027.
This one is different from everything else on the list. MAHA ELEVATE is a $100 million grant program funding up to 30 cooperative agreements over three years. The agreements will support evidence-based, whole-person care interventions, functional medicine and lifestyle medicine approaches, that Original Medicare does not currently cover. Nutrition programs. Physical activity interventions. Stress management protocols. Sleep improvement strategies. Harmful substance avoidance counseling. Social connection initiatives. Three awards are reserved specifically for dementia-related interventions.
Eligible applicants include private practices, health systems, ACOs, academic institutions, and functional or integrative medicine centers. Each proposal must incorporate nutrition or physical activity. Each must demonstrate that the proposed intervention is safe, effective, and supported by peer-reviewed literature. CMS is explicit that these approaches are intended to support conventional medicine, not replace it.
The purpose is data collection. Nearly 45 percent of Medicare beneficiaries had four or more chronic conditions in 2022, and patients with chronic conditions accounted for roughly 90 percent of total health care spending. CMS wants to know whether investing in upstream behavioral and lifestyle interventions measurably bends the cost curve and improves outcomes. If the data shows they do, future coverage decisions follow.
MAHA ELEVATE is the first Innovation Center model to focus on proactive prevention through functional and lifestyle medicine. The political framing is obvious in the name. The clinical question underneath the politics is legitimate, and CMS is spending $100 million to answer it.
BALANCE
The Better Approaches to Lifestyle and Nutrition for Comprehensive Health Model addresses GLP-1 medications. These are the semaglutide and tirzepatide drugs that have reshaped the weight-loss landscape over the past two years, drugs that cost upwards of $1,000 per month at list price and that Medicare and Medicaid have struggled to cover.
Under BALANCE, CMS negotiates pricing with GLP-1 manufacturers on behalf of state Medicaid agencies and Medicare Part D plan sponsors. Participating states can begin covering GLP-1s for weight management as early as May 2026. Medicare Part D coverage is anticipated to begin in January 2027. A separate GLP-1 payment demonstration will bridge the gap, launching in July 2026 to give Medicare beneficiaries access to negotiated prices before the full model starts in Part D.
Beneficiaries receiving GLP-1s for weight management will also be connected to lifestyle support programs. The model pairs the pharmacological intervention with behavioral and nutritional counseling. Manufacturer applications were due January 8, 2026, along with notices of intent from states and Part D plans. The model runs through December 2031.
BALANCE matters because it creates a federal pathway for weight-management coverage that has not existed in Medicare and has been uneven across Medicaid. The drugs work. The coverage question has been cost. CMS is attempting to solve the cost question through centralized negotiation.
GENEROUS
The GENErating cost Reductions fOr U.S. Medicaid Model launched on a rolling basis starting January 1, 2026. It runs for five years. Participation is voluntary for both manufacturers and states.
GENEROUS applies international reference pricing to Medicaid. Participating manufacturers offer lower prices on their portfolio of covered outpatient drugs, with pricing calculated from select international pricing data. States that join the model access those lower prices through supplemental rebate agreements negotiated by CMS.
Net Medicaid drug spending hit $60 billion in 2024, a $10 billion increase from 2022. Total spending before rebates exceeded $100 billion. GENEROUS builds on the existing Medicaid Drug Rebate Program and on CMS's experience negotiating cell and gene therapy pricing through earlier models.
Manufacturer applications are open through March 31, 2026. States can enroll on a rolling basis through August 31, 2026. All 50 states are eligible.
GLOBE and GUARD
These two proposed mandatory models target drug pricing from the Medicare side. Both are in the comment period, with public input due by February 23, 2026. Both use international reference pricing benchmarked against 19 OECD countries.
GLOBE, the Global Benchmark for Efficient Drug Pricing Model, applies to Medicare Part B drugs, the physician-administered medications like cancer therapies, autoimmune treatments, and injectable biologics that drive a significant share of Part B spending. More than two-thirds of Part B drug spending, roughly $46 billion annually, falls in the single-source drug and sole-source biologic category that GLOBE targets. The model would launch October 1, 2026, and run five years. It applies to 25 percent of Medicare beneficiaries in randomly selected zip code areas. Manufacturers whose drugs exceed the international benchmark would owe rebates. Beneficiary coinsurance would drop to reflect the lower benchmark price.
GUARD, the Guarding U.S. Medicare Against Rising Drug Costs Model, applies the same logic to Medicare Part D, the retail and mail-order pharmacy benefit. Part D gross drug spending jumped from $121 billion in 2014 to $276 billion in 2023. GUARD would launch January 1, 2027, and run through 2031. CMS estimates $14.1 billion in savings between 2028 and 2033.
If both models are finalized as proposed, CMS will have implemented international reference pricing across both Medicare drug benefits simultaneously. Americans currently pay roughly three times what other developed nations pay for the same medications.
GLOBE and GUARD propose to close that gap through the rebate mechanism rather than through direct price controls, a distinction that matters legally and politically, even if the practical effect on manufacturer revenue is similar.
LEAD
The Long-term Enhanced ACO Design Model is a ten-year voluntary program beginning January 1, 2027. Applications open in March 2026.
LEAD is CMS's next-generation Accountable Care Organization model, designed to reach the providers who have never joined an ACO. Prior models have favored large, well-resourced health systems in urban areas. LEAD adjusts the benchmarking methodology and payment design to make participation viable for smaller, independent, and rural practices, and for practices serving patients with complex care needs.
The model includes prospective population-based payments to support team-based care, integrated support for patients with behavioral health and social needs, and new waivers and flexibilities including a Substance Access Beneficiary Engagement Incentive that allows participants to consult with patients about eligible hemp products in states where legal.
LEAD also includes a Medicaid integration component. During a planning phase from March 2026 through December 2027, CMS will identify two states to pilot ACO-Medicaid partnership arrangements aimed at improving care coordination for dually eligible beneficiaries.
Rural Health Transformation
All 50 states will receive awards under the Rural Health Transformation Program, a $50 billion initiative established under the Working Families Tax Cuts legislation. First-year awards in 2026 will average $200 million per state, within a range of $147 million to $281 million. The funding supports expanded access to care in rural communities, workforce development, facility modernization, and technology infrastructure.
What It Adds Up To
Count the models and you count the federal government's theory of what is wrong with American health care, rendered in payment policy.
Chronic disease costs too much because fee-for-service rewards activity over outcomes. ACCESS fixes that. Surgical care is fragmented and wasteful. TEAM fixes that. Prevention is underfunded and undervalued. MAHA ELEVATE tests whether funding it works. Obesity drugs exist that could prevent billions in downstream chronic disease spending, and neither Medicare nor most state Medicaid programs cover them. BALANCE fixes that. Drug prices in the United States bear no relationship to drug prices anywhere else in the industrialized world. GENEROUS, GLOBE, and GUARD fix that, or try to. ACOs have not reached the providers who need them most. LEAD fixes that. Rural health infrastructure is crumbling. RHT funds the rebuild.
Each model carries risk. TEAM forces hospitals into financial accountability they may lack the infrastructure to manage. GLOBE and GUARD face certain legal challenge from pharmaceutical manufacturers. MAHA ELEVATE is spending $100 million on a hypothesis. ACCESS depends on a digital health industry that has promised more than it has delivered.
The deadline for the first ACCESS is April 1. TEAM is already live. MAHA ELEVATE's NOFO drops any day. The comment period on GLOBE and GUARD closed February 23. The window for engagement is open and it will not stay open indefinitely.
Experts Ready to Connect
These nine models represent the most significant shift in Medicare and Medicaid payment policy in years, and the timelines are tight.
Whether you're evaluating ACCESS for your chronic care management program, preparing for TEAM's mandatory bundled payments, or exploring how LEAD could work for your practice, the decisions you make will shape your reimbursement landscape for the next decade. Advanta's Medicare specialists work with practices every day to navigate exactly these kinds of transitions.
If you want to understand what these models mean for your patient population, your revenue, and your operations, reach out to our team. We'll walk through the specifics together.